Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood drug levels may predict recovery after brain bleed

NCT ID NCT07065903

Knowledge-focused Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 500 adults in Canada and the US who have had a brain aneurysm bleed and are taking the drug nimodipine. Researchers will measure how much of the drug gets into each patient's blood and see how that relates to their recovery 90 days later. The goal is to understand if different doses or forms of nimodipine affect outcomes, which could lead to more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nimodipine
What this could lead to
If successful, this could lead to personalized nimodipine dosing for patients with brain aneurysm bleeds, potentially improving recovery and reducing disability.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may show associations but not prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted for SAH to any of the participating centres.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-85 years * Diagnosis of aneurysmal SAH * Provision of informed consent * Treated with nimodipine * Presence of intravascular catheter at the time of sampling Exclusion Criteria: * Anticipated hospital length of stay \<48 hours * Non-aneurysmal SAH * Not treated with nimodipine * Incarceration * Delayed presentation to the hospital (\>96 h from SAH onset)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subarachnoid aneurysm hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subarachnoid aneurysm hemorrhage Subarachnoid hemorrhage, aneurysmal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Health Network - Toronto Western Hospital

    RECRUITING

    Toronto, Ontario, M5T 2S8, Canada

  • University of Alberta Hospital

    RECRUITING

    Edmonton, Alberta, T6G 2X8, Canada

  • VCU Medical Center

    RECRUITING

    Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.